Luis Martinez-Lostao
Overview
Explore the profile of Luis Martinez-Lostao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez Perez J, Inda-Landaluce M, Nocito-Colon M, Martinez-Lostao L
Ther Drug Monit
. 2025 Jan;
PMID: 39853305
Background: Tumor necrosis factor is a crucial proinflammatory cytokine in immune-mediated diseases. Tumor necrosis factor inhibitors (TNFi), such as infliximab and adalimumab, effectively treat rheumatological and digestive disorders. However, challenges...
2.
Sesma A, Pardo J, Isla D, M Galvez E, Gascon-Ruiz M, Martinez-Lostao L, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199571
The development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC)...
3.
Garcia-Alvarez F, Chueca-Marco A, Martinez-Lostao L, Aso-Gonzalvo M, Estella-Nonay R, Albareda J
Injury
. 2024 Jul;
55 Suppl 5:111736.
PMID: 39068064
Objectives: Ageing may cause a progressive pro-inflammatory environment and alter functionality of different immune-cell populations. The aim of the present study is to examine the influence of certain serum immunological...
4.
Zapata-Garcia M, Moratiel-Pellitero A, Isla D, Galvez E, Gascon-Ruiz M, Sesma A, et al.
Heliyon
. 2024 Jul;
10(13):e33684.
PMID: 39050456
Lung cancer is a leading cause of morbidity and mortality globally, with its high mortality rate attributed mainly to non-small cell lung cancer (NSCLC). Although immunotherapy with immune checkpoint inhibitors...
5.
Moratiel-Pellitero A, Zapata-Garcia M, Gascon-Ruiz M, Sesma A, Quilez E, Ramirez-Labrada A, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539479
Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain...
6.
Lopez-Perez J, Martinez-Lostao L, Inda-Landaluce M
HLA
. 2024 Feb;
103(2):e15415.
PMID: 38372620
The novel HLA-C*01:65:02 allele was detected during routine HLA typing.
7.
Morte-Romea E, Pesini C, Pellejero-Sagastizabal G, Letona-Gimenez S, Martinez-Lostao L, Aranda S, et al.
Front Immunol
. 2024 Feb;
15:1289303.
PMID: 38352878
Immunotherapy treatments aim to modulate the host's immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during...
8.
Martinez-Dominguez S, Garcia-Mateo S, Sainz-Arnal P, Martinez-Garcia J, Gallego-Llera B, Lozano-Limones M, et al.
Sci Rep
. 2023 Dec;
13(1):23061.
PMID: 38155275
Suboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October...
9.
Calvo J, Santiago L, Arias M, Pardo J, Albareda J, Martinez-Lostao L, et al.
Jt Dis Relat Surg
. 2023 Jul;
34(2):271-278.
PMID: 37462629
Objectives: This study aims to assess the development of osteoarthritis (OA) in granzyme A- (gzmA) and B- (gzmB) and perforin- (perf) knockout mice. Materials And Methods: A total of 75...
10.
Marco-Brualla J, de Miguel D, Martinez-Lostao L, Anel A
J Clin Med
. 2023 Jan;
12(2).
PMID: 36675536
Cancer resistance to treatments is a challenge that researchers constantly seek to overcome. For instance, TNF-related apoptosis-inducing ligand (TRAIL) is a potential good prospect as an anti-cancer therapy, as it...